-
公开(公告)号:EP2210880A1
公开(公告)日:2010-07-28
申请号:EP08836571.3
申请日:2008-10-02
IPC分类号: C07D239/80 , A61K31/517 , A61K31/536 , A61P1/00 , A61P1/04 , A61P1/10 , A61P1/16 , A61P1/18 , A61P3/00 , A61P3/04 , A61P3/06 , A61P3/10 , A61P3/12 , A61P5/00 , A61P5/24 , A61P9/00 , A61P9/04 , A61P9/06 , A61P9/10 , A61P9/12 , A61P11/00
CPC分类号: C07D239/80 , C07D265/18 , C07D403/04 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D498/04
摘要: [PROBLEMS]
To provide a compound useful as an agent for the treatment of circulatory diseases, nervous system diseases, metabolic diseases, reproductive system diseases, and digestive tract diseases.
[MEANS FOR SOLVING PROBLEMS]
The compound, which is for use as an active ingredient, is represented by the formula (I):
[wherein R 1 represents optionally halogenated C 1-6 alkyl, etc.; R 2 represents, e.g., a group represented by the formula (II-1) or (II-4)
(wherein W represents C 1-6 alkylene, etc. and R represents C 1-6 alkyl, etc.); R 3 represents hydrogen, C 1-6 alkyl, etc.; X represents -O-, -NH-, etc.; and Y 1 , Y 2 , Y 3 , and Y 4 each independently represents -CH-, -N-, etc.].摘要翻译: [问题]提供可用作治疗循环系统疾病,神经系统疾病,代谢疾病,生殖系统疾病和消化道疾病的药物的化合物。 [用于解决课题的手段]用作有效成分的化合物由式(I)表示:[其中,R 1表示可以被卤素化的C 1-6烷基等。 R2表示例如由式(II-1)或(II-4)表示的基团(其中W表示C1-6亚烷基等,R表示C1-6烷基等)。 R3代表氢,C1-6烷基等; X表示-O - , - NH-等; Y 1,Y 2,Y 3和Y 4各自独立地表示-CH - , - N-等]。